U.S. product exclusion extensions, Section 301 action concerning medical-care products from China (COVID-19)
A notice of product exclusion extensions concerning the Section 301 investigation
A notice of product exclusion extensions concerning the Section 301 investigation
The Office of the U.S. Trade Representative posted on its website a notice of product exclusion extensions concerning the Section 301 investigation of China’s acts, policies, and practices related to technology transfer, intellectual property, and innovation.
Prior notices excluded from additional duties certain medical-care products that were to address the coronavirus (COVID-19) pandemic. The USTR in May 2022 determined to extend 81 of the product exclusions through November 30, 2022. Read TradeNewsFlash
The USTR notice [PDF 118 KB] announces the determination to further extend certain product exclusions—that is, to remove Section 301 customs duties from medical-care products that address COVID-19—through February 28, 2023.
U.S. Customs and Border Protection (CBP) on December 1, 2022, released instructions for importers, brokers, and filers on submitting entries to CBP containing granted exclusions by the USTR from the Section 301 measures—CSMS # 54197079.
For more information, contact a professional with KPMG’s Trade & Customs services:
Doug Zuvich |
John L. McLoughlin |
Andy Siciliano |
Steve Brotherton |
Luis (Lou) Abad |
Irina Vaysfeld |
Amie Ahanchian |
Christopher Young |
Gisele Belotto |
George Zaharatos |
Andy Doornaert |
Jessica Libby Principal E: jlibby@kpmg.com |
The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization. KPMG International Limited is a private English company limited by guarantee and does not provide services to clients. No member firm has any authority to obligate or bind KPMG International or any other member firm vis-à-vis third parties, nor does KPMG International have any such authority to obligate or bind any member firm. The information contained herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation. For more information, contact KPMG's Federal Tax Legislative and Regulatory Services Group at: + 1 202 533 3712, 1801 K Street NW, Washington, DC 20006.